Casdin: Big pharma spent 20 years jettisoning internal R&D
Eli Casdin · Eli Casdin – Casdin Capital (Manager Meetings, EP.02) · Jul 15, 2021 · at 26:15
Eli Casdin discusses why large pharmaceutical incumbents struggle to drive organic drug innovation compared to nimble biotech firms.
0:00 / 0:07exact quote · 7.3s
720p mp4 · rendered on demand · StarZero watermark
“And so I think pharma in the last 20 years had jettisoned their R&D efforts to focus on distribution of brand.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Eli Casdin
Casdin: Biotechs no longer need big pharma to commercialize drugs
“Investors like me are saying, don't sell yourself. Don't partner. You don't need them. I'll give you the money. Go at it alone. Build out commercial. Become your own standalone company, and many, many more are going that path, and I think that they don't need …”
Casdin: Scaling check sizes over time de-risks capital-intensive life sciences investing
“What typical venture investors try to get as much money in, in their first slug, and then they fight dilution on the way down. What we're doing is scaling up over time because these companies are burning a hundred to a hundred and fifty million dollars every 1…”
Casdin: High event catalysts are negatively correlated with investment returns
“What we learned was that high catalysts were negatively correlated with return. And low catalyst actually was positive quarterly.”
Casdin: Drug development success rates will rise and costs will fall
“Our industry over the next 10 years, and I can say that comfortably, drugs are going to be higher chance of approval, higher chance of efficacy. Probability of success is going to go up continually, and cost of that success is going to come down.”